Tiziana Life Sciences plc announced the addition of two key members: Professors Kevan Herold, MD and Howard Weiner, MD who will be joining its Scientific Advisory Board and focusing on pioneering a unique clinical development plan for foralumab. Dr. Kevan Herold is Professor of Immunobiology and of Medicine (Endocrinology) as well as Deputy Director, Yale Center for Clinical Investigation, Director of the Yale Diabetes Center and Director of the TrialNet Center at Yale. Dr. Howard Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis (MS) Center and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital in Boston.